reviewnonsteroidal anti-inflammatory drugsenteropathyinflammationpermeability of intestinal walliron deficiencyhypoalbuminemiaобзорнестероидные противовоспалительные препаратыэнтеропатиявоспалениепроницаемость кишечной стенкижелезодефицитгипоальбуминемия1.Каратеев А. Е., Насонов Е. Л. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Рус. мед. журн. 2006; 25: 176-177.2.Maiden L., Thjodleifsson B., Seigal A. et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin. Gastroenterol. Hepatol. 2007; 9: 1040-1045.3.Maiden L., Thjodleifsson B., Theodors A. et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128 (5): 1172-1178.4.Shitrit A. B., Braverman D., Stankiewics H. et al. Fecal calprotectin as a predictor of abnormal colonic histology. Dis. Colon Rect. 2007; 50 (12): 2188-2193.5.Goldstein J. L., Eisen G. M., Lewis B. et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Clin. Gastroenterol. Hepatol. 2007; 3 (1): 55-59.6.Tibble J. A., Sigthorsson G., Foster R., Bjarnason I. Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scand. J. Gastroenterol. 2000; 35 (8): 802-807.7.Davies N. M., Saleh J. Y., Skjodt N. M. Detection and prevention of NSAID-induced enteropathy. J. Pharm. Pharm. Sci. 2000; 3 (1): 137-155.8.Tibble J. A., Sigthorsson G., Foster R. et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999; 45 (3): 362-366.9.Bogas M., Afonso Mdo C., Araъjo D. Non-steroidal anti-inflammatory drugs and lower intestinal tract toxicity. Acta Reumatol. Port. 2006; 31 (3): 227-235.10.Thiefin G., Beaugerie L. Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine 2005; 72 (4): 286-294.11.Shah A. A., Thjodleifsson B., Murray F. E. et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001; 48 (3): 339-346.12.Smecuol E., Bai J. C., Sugai E. et al. Acute gastrointestinal permeability responses to different non-streroidal anti-inflammatory drugs. Gut 2001; 49 (5): 650-655.13.Насонов Е. Л. Нестероидные противовоспалительные препараты: терапевтические перспективы. Рус. мед. журн. 2002: 10 (4): 206-212.14.Fortun P. J., Hawkey C. J. Nonsteroidal anti-inflammatory drugs and the small intestine. Curr. Opin. Gastroenterol. 2005; 21: 169-175.15.Fortun P. J., Hawkey C. J. Nonsteroidal anti-inflammatory drugs and the small intestine. Curr. Opin. Gastroenterol. 2007; 23 (2): 134-141.16.Sightorsson G., Tibble J., Hayllar J. et al. Intestinal permeability an inflammation in patients on NSAIDs. Gut 1998; 43: 506-511.17.Thornjурleifsson B., Theodуrs A., Bjarnason I. The effect of diclofenac on the small intestine studied by wireless endoscopy. Laeknabladid 2004; 90 (10): 689-693.18.Davies N. M., Wright M. R., Jamali F. Anti-inflammatory drug-induced small intestinal permeability: the rat is a suitable model. Pharmacol. Res. 1994; 11 (11): 1652-1656.19.Bjarnason I., Hayllar J., Macpherson A. J., Russele A. S. Side effect of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-1847.20.Bjarnason I., Williams P., So A. et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet 1984; 2 (8413): 1171-1174.21.Bjarnason I., Zanelli G., Prouse P.et al. Effect of non-steroidal anti-inflammatory drugs on the human small intestine. Drugs 1986; 32 (suppl. 1): 35-41.22.Jenkins R. T., Rooney P. J., Jones D. B. et al. Increased intestinal permeability in patients with rheumatoid arthritis: a side-effect of oral nonsteroidal anti-inflammatory drug therapy? Br. J. Rheumatol. 1987; 26 (2): 103-107.23.Bjarnason I., Zanelli G., Smith T. et al. Nonsteroidal anti-inflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987; 93 (3): 480-489.24.Fagiolo U., Paganelli R., Ossi E. et al. Intestinal permeability an antigen absorption in rheumatoid arthritis. Effects of acetylsalicylic acid an sodium chromoglycate. Int. Arch. Allergy Appl. Immunol. 1989; 89 (1): 98-102.25.Чичасова Н. В. Эффективность нестероидных противовоспалительных препаратов в клинической практике. Рус. мед. журн. 2006; 25: 179.26.Tugendreich S., Pearson C. I., Sagartz J. et al. Nsaid-induced acute phase response is due to increased intestinal permeability and characterized by early and consistent alterations in hepatic gene expression. Toxicol. Pathol. 2006; 34 (2): 168-179.27.Пасечников В. Д., Бобрышев Д. В., Витковский Ю. В. Нестероидные гастропатии: опыт использования арторотека. Medical Market 1997; 25: 46-47.28.Nalbant S., Akmaz I., Kaplan M. et al. Does rofecoxib increase TNF-alpha levels? Clin. Exp. Rheumatol. 2006; 24 (4): 361-365.29.Lanas A., Scarpignato C. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? Digestion 2006; 73 (suppl. 1): 136-150.30.de Vries-Bouwstra J. K., Goekoop-Ruiterman Y. P., Wesoly J. et al. Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide stimulation is associated with rheumatoid arthritis and with joint damage. Ann. Rheum. Dis. 2007; 66 (8): 1033-1037.31.Deng X., Stachlewitz R. F., Liguori M. J. et al. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J. Pharmacol. Exp. Ther. 2006; 319 (3): 1191-1199.32.Graham D. Y., Opekun A. R., Willingham F. F., Qureshi W. A. Visible small-intestinal mucosal injury in chronic NSAID users. Aliment. Pharmacol. Ther. 2007; 25 (10): 1211-1222.33.Adebayo D., Bjarnason I. Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad. Mjed. J. 2006; 82 (965): 186-191.34.Menozzi A., Pozzoli C., Giovannini E. et al. Intestinal effects of nonselective and selective cyclooxygenase inhibitors in the rat. Eur. J. Pharmacol. 2006; 552 (1-3): 143-150.35.Stuart C. A., Twistelton R., Nicholas M. K., Hide D. W. Passage of cows milk proteins in breast milk. Clin. Allergy 1984; 14: 533-535.36.Низов А. А., Гмошинский И. В., Луняков А. С. и др. Проницаемость барьера желудочно-кишечного тракта для белкового антитела у больных с пищевой аллергией и некоторыми сопутствующими заболеваниями органов пищеварения. Рос. журн. гастроэнтерол., гепатол., колопроктол. 1996; 3: 26-30.37.Мазо В. К., Гмошинский И. В., Четверикова Н. Ю. и др. Методы количественной оценки проницаемости кишечного барьера для белковых макромолекул у взрослых и детей: состояние вопроса и перспективы. В кн.: III Международная конф. и дискуссионный клуб ?Новые информационные технологии в медицине и экологии?: Тезисы докладов. Ялта-Гурзуф; 1997. 43-46.38.Насонов Е. Л. Нестероидные противовоспалительные препараты: проблемы безопасности лечения. Consilium Medicum 1999; 1 (5): 37-43.39.Kim J. W., Jeon W. K., Kim E. J. Combined effects of bovine colostrum and glutamine in diclofenac-induced bacterial translocation in rat. Clin. Nutr. 2005; 24 (5): 785-793.40.Bours M. J., Troost F. J., Brummer R. J. et al. Local effect of adenosine 5?-triphosphate on indomethacin-induced permeability changes in the human small intestine. Eur. J. Gastroentrol. Hepatol. 2007; 19 (3): 245-250.